

Marek Postula

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6140760/publications.pdf>

Version: 2024-02-01

86
papers

1,877
citations

331259

21
h-index

329751

37
g-index

89
all docs

89
docs citations

89
times ranked

2643
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiplatelet drugs and liver fibrosis. <i>Platelets</i> , 2022, 33, 219-228.	1.1	11
2	Flow-Responsive Noncoding RNAs in the Vascular System: Basic Mechanisms for the Clinician. <i>Journal of Clinical Medicine</i> , 2022, 11, 459.	1.0	5
3	The role of miRNAs in regulation of platelet activity and related diseases - a bioinformatic analysis. <i>Platelets</i> , 2022, 33, 1052-1064.	1.1	13
4	High concentration of symmetric dimethylarginine is associated with low platelet reactivity and increased bleeding risk in patients with acute coronary syndrome. <i>Thrombosis Research</i> , 2022, 213, 195-202.	0.8	0
5	Diagnostic Performance of Circulating miRNAs and Extracellular Vesicles in Acute Ischemic Stroke. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4530.	1.8	8
6	The role of non-coding RNAs in neuroinflammatory process in multiple sclerosis. <i>Molecular Neurobiology</i> , 2022, 59, 4651-4668.	1.9	3
7	Alteration of circulating platelet-related and diabetes-related microRNAs in individuals with type 2 diabetes mellitus: a stepwise hypoglycaemic clamp study. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	11
8	Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS. <i>Platelets</i> , 2021, 32, 498-506.	1.1	3
9	Long Non-coding RNAs as Promising Therapeutic Approach in Ischemic Stroke: a Comprehensive Review. <i>Molecular Neurobiology</i> , 2021, 58, 1664-1682.	1.9	30
10	The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke. <i>Molecular Neurobiology</i> , 2021, 58, 329-347.	1.9	78
11	Plasma Concentrations of Extracellular Vesicles Are Decreased in Patients with Post-Infarct Cardiac Remodelling. <i>Biology</i> , 2021, 10, 97.	1.3	8
12	Deformation Parameters of the Heart in Endurance Athletes and in Patients with Dilated Cardiomyopathy – A Cardiac Magnetic Resonance Study. <i>Diagnostics</i> , 2021, 11, 374.	1.3	12
13	MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics. <i>Cardiovascular Diabetology</i> , 2021, 20, 55.	2.7	53
14	Can We Provide Safe Training and Competition for All Athletes? From Mobile Heart Monitoring to Side Effects of Performance-Enhancing Drugs and MicroRNA Research. <i>Diagnostics</i> , 2021, 11, 492.	1.3	2
15	Epicardial Adipose Tissue and Cardiovascular Risk Assessment in Ultra-Marathon Runners: A Pilot Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3136.	1.2	7
16	Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2021, 10, 1024.	1.0	19
17	MicroRNA as Potential Biomarkers of Platelet Function on Antiplatelet Therapy: A Review. <i>Frontiers in Physiology</i> , 2021, 12, 652579.	1.3	25
18	MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine</i> , 2021, 10, 2371.	1.0	16

#	ARTICLE	IF	CITATIONS
19	Resistin is Associated with Inflammation and Renal Function, but not with Insulin Resistance in Type 2 Diabetes. <i>Hormone and Metabolic Research</i> , 2021, 53, 478-484.	0.7	2
20	Infections as Novel Risk Factors of Atherosclerotic Cardiovascular Diseases: Pathophysiological Links and Therapeutic Implications. <i>Journal of Clinical Medicine</i> , 2021, 10, 2539.	1.0	16
21	Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis. <i>Vascular Pharmacology</i> , 2021, 138, 106858.	1.0	6
22	HR Max Prediction Based on Age, Body Composition, Fitness Level, Testing Modality and Sex in Physically Active Population. <i>Frontiers in Physiology</i> , 2021, 12, 695950.	1.3	17
23	Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 691907.	1.1	26
24	Alterations in Circulating MicroRNAs and the Relation of MicroRNAs to Maximal Oxygen Consumption and Intimaâ€Media Thickness in Ultra-Marathon Runners. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7234.	1.2	7
25	Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3797-3808.	1.6	7
26	Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112169.	2.5	22
27	The Importance of Non-Coding RNAs in Neurodegenerative Processes of Diabetes-Related Molecular Pathways. <i>Journal of Clinical Medicine</i> , 2021, 10, 9.	1.0	24
28	Plasma Trimethylamine-N-Oxide Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 728724.	1.1	9
29	Altered Circulating MicroRNA Profiles After Endurance Training: A Cohort Study of Ultramarathon Runners. <i>Frontiers in Physiology</i> , 2021, 12, 792931.	1.3	9
30	Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2643-2656.	1.1	62
31	Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction. <i>Platelets</i> , 2020, 31, 26-32.	1.1	18
32	Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 609-623.	1.9	46
33	MicroRNAs and Long Noncoding RNAs in Coronary Artery Disease. <i>Cardiology Clinics</i> , 2020, 38, 601-617.	0.9	12
34	ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3743.	1.0	74
35	Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome. <i>Vascular Pharmacology</i> , 2020, 135, 106806.	1.0	18
36	MicroRNAs as Biomarkers of Systemic Changes in Response to Endurance Exerciseâ€A Comprehensive Review. <i>Diagnostics</i> , 2020, 10, 813.	1.3	20

#	ARTICLE	IF	CITATIONS
37	Early Biomarkers of Neurodegenerative and Neurovascular Disorders in Diabetes. <i>Journal of Clinical Medicine</i> , 2020, 9, 2807.	1.0	45
38	Role of P2Y Receptors in Platelet Extracellular Vesicle Release. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6065.	1.8	21
39	Factors Related to Cardiac Troponin T Increase after Participation in a 100 Km Ultra-Marathon. <i>Diagnostics</i> , 2020, 10, 167.	1.3	8
40	Non-Vitamin K Oral Anticoagulants (NOAC) versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type. <i>Journal of Clinical Medicine</i> , 2020, 9, 1120.	1.0	26
41	Effects of Environmental Factors on Severity and Mortality of COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 607786.	1.2	40
42	Are adipokines associated with atrial fibrillation in type 2 diabetes?. <i>Endokrynologia Polska</i> , 2020, 71, 34-41.	0.3	4
43	Resistin is a prognostic factor for death in type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3098.	1.7	19
44	MicroRNAs fingerprint of bicuspid aortic valve. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 134, 98-106.	0.9	25
45	Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. <i>BMC Medicine</i> , 2019, 17, 198.	2.3	71
46	Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review. <i>Cardiovascular Diabetology</i> , 2019, 18, 113.	2.7	111
47	Switching between P2Y12 antagonists – From bench to bedside. <i>Vascular Pharmacology</i> , 2019, 115, 1-12.	1.0	8
48	Effectiveness of Antiplatelet Drugs Under Therapeutic Hypothermia: A Comprehensive Review. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 993-1005.	2.3	7
49	Left ventricular hypertrophy in middle-aged endurance athletes. <i>Blood Pressure Monitoring</i> , 2019, 24, 110-113.	0.4	14
50	Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 176.	1.1	17
51	Bioresorbable Vascular Scaffolds – Dead End or Still a Rough Diamond?. <i>Journal of Clinical Medicine</i> , 2019, 8, 2167.	1.0	18
52	Serum Brain-Derived Neurotrophic Factor is Related to Platelet Reactivity and Metformin Treatment in Adult Patients With Type 2 Diabetes Mellitus. <i>Canadian Journal of Diabetes</i> , 2019, 43, 19-26.	0.4	19
53	The role of acetylsalicylic acid and circulating microRNAs in primary prevention of cardiovascular events in patients with Diabetes Mellitus Type 2 – A Review. <i>Annals of Agricultural and Environmental Medicine</i> , 2019, 26, 512-522.	0.5	3
54	Increased burden of rare deleterious variants of the KCNQ1 gene in patients with large-vessel ischemic stroke. <i>Molecular Medicine Reports</i> , 2019, 19, 3263-3272.	1.1	3

#	ARTICLE	IF	CITATIONS
55	MicroRNAs as Diagnostic and Prognostic Biomarkers in Ischemic Stroke – A Comprehensive Review and Bioinformatic Analysis. <i>Cells</i> , 2018, 7, 249.	1.8	131
56	Ticagrelor – toward more efficient platelet inhibition and beyond. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 129-140.	0.9	47
57	The Potential Role of Platelet-Related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review. <i>Frontiers in Endocrinology</i> , 2018, 9, 74.	1.5	92
58	Genetic Variability of SRC Family Kinases and Its Association with Platelet Hyperreactivity and Clinical Outcomes: A Systematic Review. <i>Current Pharmaceutical Design</i> , 2018, 24, 628-640.	0.9	8
59	New single-nucleotide polymorphisms associated with differences in platelet reactivity and their influence on survival in patients with type 2 diabetes treated with acetylsalicylic acid: an observational study. <i>Acta Diabetologica</i> , 2017, 54, 343-351.	1.2	9
60	Association of frequent genetic variants in platelet activation pathway genes with large-vessel ischemic stroke in Polish population. <i>Platelets</i> , 2017, 28, 66-73.	1.1	9
61	Population-Specific Associations of Deleterious Rare Variants in Coding Region of P2RY1 and P2RY12 Purinergic Receptor Genes in Large-Vessel Ischemic Stroke Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2678.	1.8	10
62	Antidiabetic Effect of Brain-Derived Neurotrophic Factor and Its Association with Inflammation in Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2017, 2017, 1-14.	1.0	75
63	Common Polymorphisms within Genes Encoding Platelet Receptors: Still a Way to Go?. <i>Cardiology</i> , 2016, 133, 54-55.	0.6	0
64	Analysis of Common Single Nucleotide Polymorphisms in Complex Regional Pain Syndrome: Genome Wide Association Study Approach and Pooled DNA Strategy. <i>Pain Medicine</i> , 2016, 17, 2344-2352.	0.9	19
65	Common genetic variants in platelet surface receptors and its association with ischemic stroke. <i>Pharmacogenomics</i> , 2016, 17, 953-971.	0.6	12
66	Targeted deep resequencing of ALOX5 and ALOX5AP in patients with diabetes and association of rare variants with leukotriene pathways. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 415-421.	0.8	6
67	Next-generation re-sequencing of genes involved in increased platelet reactivity in diabetic patients on acetylsalicylic acid. <i>Platelets</i> , 2016, 27, 357-364.	1.1	7
68	Serum Brain-Derived Neurotrophic Factor is Related to Platelet Reactivity but not to Genetic Polymorphisms within BDNF Encoding Gene in Patients with Type 2 Diabetes. <i>Medical Science Monitor</i> , 2016, 22, 69-76.	0.5	18
69	Association of adipokines and inflammatory markers with lipid control in type 2 diabetes. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 414-423.	0.3	13
70	Effect of common single nucleotide polymorphisms in COX-1 gene on related metabolic activity in diabetic patients treated with acetylsalicylic acid. <i>Archives of Medical Science</i> , 2014, 6, 1198-1205.	0.4	2
71	Emerging treatments in type 2 diabetes: focus on canagliflozin. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 683.	0.9	13
72	Effect of cold perfusion and perfluorocarbons on liver graft ischemia in a donation after cardiac death model. <i>Journal of Surgical Research</i> , 2014, 188, 517-526.	0.8	10

#	ARTICLE	IF	CITATIONS
73	New single nucleotide polymorphisms associated with differences in platelets reactivity in patients with type 2 diabetes treated with acetylsalicylic acid: genome-wide association approach and pooled DNA strategy. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 65-73.	1.0	22
74	The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study. <i>Kardiologia Polska</i> , 2013, 71, 552-557.	0.3	17
75	Increased Occurrence of Valproic Acid-Induced Hyperammonemia in Carriers of T1405N Polymorphism in Carbamoyl Phosphate Synthetase 1 Gene. <i>ISRN Neurology</i> , 2013, 2013, 1-4.	1.5	11
76	Lack of effect of common single nucleotide polymorphisms in leukotriene pathway genes on platelet reactivity in patients with diabetes. <i>Molecular Medicine Reports</i> , 2013, 8, 853-860.	1.1	4
77	Effect of common single-nucleotide polymorphisms in acetylsalicylic acid metabolic pathway genes on platelet reactivity in patients with diabetes. <i>Medical Science Monitor</i> , 2013, 19, 394-408.	0.5	9
78	Association of plasma concentrations of salicylic acid and high on ASA platelet reactivity in type 2 diabetes patients. <i>Cardiology Journal</i> , 2013, 20, 170-7.	0.5	8
79	Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: The AVOCADO study. <i>Cardiology Journal</i> , 2013, 20, 545-551.	0.5	21
80	Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. <i>Kardiologia Polska</i> , 2013, 71, 893-902.	0.3	21
81	Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with type 2 diabetes?. <i>Cardiology Journal</i> , 2012, 19, 494-500.	0.5	5
82	Genome-wide Association Study Using Pooled DNA to Identify Candidate Markers Mediating Susceptibility to Postoperative Nausea and Vomiting. <i>Anesthesiology</i> , 2011, 115, 54-64.	1.3	87
83	Factors responsible for "aspirin resistance" - can we identify them?. <i>Kardiologia Polska</i> , 2010, 68, 403-11; discussion 412-3.	0.3	11
84	Current Problems, New Opportunities and Future Directions of Antiplatelet Therapy - Increasing Role of Novel Antiplatelet Agents in Cardiovascular Diseases. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2009, 4, 55-60.	1.5	4
85	The effect of off-pump coronary artery bypass grafting on platelet activation in patients on aspirin therapy until surgery day. <i>European Journal of Cardio-thoracic Surgery</i> , 2008, 34, 365-369.	0.6	9
86	Association Between the Expression of MicroRNA-125b and Survival in Patients With Acute Coronary Syndrome and Coronary Multivessel Disease. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2